In a multicenter randomized trial, tenecteplase did not improve vision recovery compared with aspirin when given within 4.5 hours of acute central retinal artery occlusion (CRAO). The ...

Concerns arise as Medisep 2 excludes essential eye treatment for age-related macular degeneration, risking vision for Kerala’s pensioners.

INDICATIONS EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...

Intravenous tenecteplase administered within 4.5 hours after onset of central retinal artery occlusion does not improve vision recovery at 30 days compared with oral aspirin, according to a study ...

While most people won't notice symptoms of the 'silent killer' until it is too late, there are still some signs to watch out ...

A cardiologist has warned about three subtle symptoms of high blood pressure, the 'silent killer' condition that affects ...

Tenecteplase failed to outperform aspirin for vision recovery when administered within 4.5 hours of onset of acute central ...

In this randomized controlled trial of adults with central retinal artery occlusion, tenecteplase administration shortly after symptom onset did not significantly improve visual recovery. 2. Those who ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

Sharon Fekrat discusses the complexities of antithrombotic use in wet AMD, highlighting the need for individualized treatment and future guideline development. Sharon Fekrat, MD, FACS, FASRS, ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...